Selling, General, and Administrative Costs: Novo Nordisk A/S vs Catalyst Pharmaceuticals, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing costs is as crucial as innovation. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Novo Nordisk A/S and Catalyst Pharmaceuticals, Inc., from 2014 to 2023.

Novo Nordisk, a global leader in diabetes care, consistently reported SG&A expenses in the tens of billions, peaking at approximately $61.6 billion in 2023. This represents a 130% increase from 2014, reflecting their expansive global operations and marketing efforts.

In contrast, Catalyst Pharmaceuticals, a smaller player, saw its SG&A expenses grow from $4.5 million in 2014 to $133.7 million in 2023, marking a staggering 2,880% increase. This dramatic rise underscores Catalyst's aggressive growth strategy and increasing market presence.

This comparison highlights the diverse strategies and scales of operation within the pharmaceutical industry, offering insights into how companies allocate resources to maintain competitive edges.